The adjusted operational growth in medical devices was 4.3% last quarter. But then again, the only reason for the "adjusted" growth is to not count all the stuff they divested or closed, like ASP, Lifescan, and now-shuttered Animas. It's a bit dishonest because they're only counting the growing businesses they kept, while not counting the businesses they mismanaged into oblivion.
Other major competitors have managed to keep their competing businesses growing, areas which JNJ exited. Boston Scientific, Abbott, and Medtronic are still doing ok in interventional cardiology, but JNJ couldn't compete and divested Cordis.
Abbott is doing extremely well in their diagnostics business, but JNJ couldn't compete and divested OCD.
Abbott and Medtronic are growing leaps and bounds in diabetes care, but JNJ couldn't so they dumped Lifescan and Calibra and closed Animas.
Steris is growing and has been consistently executing well in sterilization and disinfection, but JNJ bungled ASP and dumped them.
Synthes was growing prior to the JNJ acquisition, and now under JNJ ownership the legacy Synthes businesses are losing market share and not growing. JNJ has begun the process of eventually divesting the entire orthopedics business. Synthes manufacturing sites have all been sold to Jabil, which is the first step in eventually divesting the whole enchilada.
With the majority of JNJ's legendary medical device franchises divested or closed due to JNJ mismanaging these businesses into the ground, what confidence should anyone have in their management to actually start "trying harder"?